Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Efficacy of treatment with XELIRI + Bevacizumab
| Tumor response | Number (%) |
|---|---|
| CR | 1 (2%) |
| PR | 6 (12%) |
| SD | 25 (50%) |
| PD | 16 (32%) |
| NE | 2 (4%) |
| RR [95% CI] | 7 (14.6%) [6.5–28.4] |
| DCR [95% CI] | 32 (66.7%) [51.5–79.2] |
All patients (N = 50)
XELIRI xeloda and irinotecan, CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluated, RR response rate, DCR disease control rate, CI confidence interval
